Similarly, sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have shown remarkable cardiovascular benefits in heart failure patients but have had the same hemodynamic consequences (Rong et al, 2020). Here, SLC5A2 is linked to heart failure.